COMMUNIQUÉS West-GlobeNewswire

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
07/08/2025
WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and [...]
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
07/08/2025
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development [...]
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
07/08/2025
Recent positive recommendation by the Independent Data Monitoring Committee (“IDMC”) to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final [...]
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
07/08/2025
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/08/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) NEW YORK, 07 août 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
07/08/2025
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 [...]
Nova Leap Health Corp. Posts Record Q2 2025 Results
07/08/2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Lifeward to Report Second Quarter Financial Results on August 14, 2025
07/08/2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of [...]
VitalHub Reports Second Quarter 2025 Results
07/08/2025
Annual Recurring Revenue (ARR) (1) up 55% YoY to $79.6 million Total Revenue up 47% YoY to $23.9 million Adjusted EBITDA (1) up 50% YoY to $6.3 million TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI [...]
Bluejay Diagnostics Provides Second Quarter Business and Corporate Update
08/08/2025
ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced [...]
PetVivo Sets Fiscal First Quarter 2026 Conference Call for Thursday, August 14, 2025 at 5:00 p.m. ET
07/08/2025
MINNEAPOLIS, MN, US, Aug. 07, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion [...]
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
07/08/2025
- Halneuron ® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35 [...]
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
07/08/2025
Appointment to Chair of the Board and Additional Growth Funding Accelerate Longeviti’s Mission in Developing Platform Solutions for Complex Neurological Disorders BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti [...]
J-Star Holding Announces Closing of Underwriters’ Over-Allotment Option in Connection with Initial Public Offering
07/08/2025
TAICHUNG CITY, Taiwan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications [...]
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
07/08/2025
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic [...]
Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology
07/08/2025
Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion SOUTH JORDAN, Utah, Aug. 07, 2025 (GLOBE [...]
Recovery.com Acquires Recovery Brands Care Navigation Platform from American Addiction Centers in Eight-Figure Deal to Expand Access to Care
07/08/2025
Strategic acquisition of premier sites doubles Recovery.com’s reach, solidifying leading market position and accelerating access to trusted treatment options for millions MADISON, Wis., Aug. 07, 2025 (GLOBE NEWSWIRE [...]
SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025
07/08/2025
DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]

Pages